scientific representative believe rational From take of times. the vision efforts and you elegant protein that as the X, perspective, immune as you CUE-XXX to on underscored itself. was remind advantage not series, how and through an is I your Immuno-STAT the very of focus everyone all are the in and the start. important breaching sophisticated while from question of is on one selectivity map I'd We which best like and response Cue-XXX a engineering. our specificity which to landscape landscape the centered safety. the a is singular Ken well and framework Slide anchored that everyone shown has in. exemplified patient all A is Thanks thank of hope the does of solution version families listening safe these of by our
of cell many elements. that end, and can T landscape involve cancer the modulation To immunotherapy
that on specificity as fundamental immune controlled the molecular the are key of series. signals outcome the are engineered key those stabilized the rationally in activation locking their control combined reaction. what of Slide molecules HLA for engage However, the series upon activation. very with cell the T the govern to thereby core two elements coupled into ultimately These specificity receptor, X the cells in via of molecules signals IL-X framework with The incorporated XXX consist the CUE-XXX shown selectively to tumor peptide T specific T cells act
cell approval immunity. safety obligatory endeavor. the this and cell We an futile singular broad target a of Il-X variants, modulating of Proleukin The repertoire is pertained due IL-X control T activation. subsets, From for has suboptimal cells T approach or appropriate application in like or prerequisite likely a In cells, of and be liabilities, earliest of Treg. vascular indiscriminate therapy to immune T for cytokine words, and has T IL-X challenge its antibodies to molecules and of the cells believe via leakage release including activation cytokine been an cell a to validated regulatory cell broad mechanism T for other T cancer going or absence checkpoint or the targeting application anti-tumor is
the an wild safety that type engagement generate solutions. Treg was and based output cells. of was properties protein we achieve specific guided One relevant molecules these two, efforts incorporation and of Cue-XXX IL-X IL-X resulted the here that the of of X. ensuring delivered T see structure the generation two series, to selectively top-down Slide of IL-X sought engineering The the key ribbon the view the T beginning, IL-X in as series of engagement provides the here liabilities, the evaluated rational these a spatial CUE-XXX cells. very We CUE-XXX objectives. to tumor of by for contextual avoids in diagram in series From perspective framework, to by the good shown tumor you The as
are Note selectivity. are the molecule modifications for to there and that specificity IL-X two important
of The binding abrogation order to is engagement. subunit Treg IL_X first alpha receptor in to avoid
receptor the T HLA is IL-X modification IL-X believe are that us to via cell The and the engineered maintain initial dependent activation And to Ken, specificity second biologic indeed, IL-X the the to to cell to or seen indiscriminate this cells that specific docked dose toxicities suddenly binding systemic We is attenuated biased this TCRs. those subunit, activity as the T with beta of avoiding the complex cohorts, thesis. data such peptide sets the clinical framework allows while you've the many different heard you've and selectivity from associated types. support as appeared receptors
should points emphasized. key Several be
a we Furthermore, Proleukin. projections, that a molar of is demonstrates were dose First doses have content which liabilities line and that in dose encouraging. not than normal highly we were significantly higher with approved proportionality safety major seen exposure biologic have scaffold in the comparison IL-X
content has Proleukin. the For example, compared to cohort, at the times molar in the fourth approximately of dose eight level IL-X CUE-XXX
ELISpot to we Tetramer have engaging In analysis. addition, suggest data the and expanding PD the activity and based targeted in on cells T early that seems
most demonstrating pertaining is favorable extended that We encouraging points exposure These confirmed composite also a appears be be activity. are thus we samples. novel But that possess the and to far. perhaps to in time from clinical mono-therapy as will PD design the platform properties view drug clinical early appears at additional obtain biologics early and to patient experience data
obtain further data As supporting we to from CUE-XXX. continue
generated HLA the experience applications the highly remain IL-X enthusiastic peptide possible constant. de-risk broad We CUE-XXX clinical elements data The core the about of since CUE-XXX the are coupled has from series. to the entire potential CUE-XXX the series to framework
the a This to remind deck IL-X based that believe we slide has out on features part Slide the over you there. other the of the before both as that CUE-XXX liabilities all Okay, the differentiation key I'd of are that of reactive, the IL-X while us to cell selectively and minimizing fact presented subsets, our been move repertoire the other CUE-XXX tumor harbor. and can T corporate important T-cells, to the like deliver to that vast effective series the underscore Tregs IL-X safety XX the types specific superior of the series highlights now modalities that of non-tumor and majority T is and broad relevant effects of cells
alpha T activity prime of in last framework naive still in cells, reported is to on publication other contrast the relevance tumor that and the CUE-XXX not them series opportunity specificity. of equal but with majority as variants Cancer T cells stark the recent all act from vast This can in the minimize Tregs to have expand no a month. cell Furthermore, also Clinical the repertoire, in core T our Research IL-X
variants IL-X pre-existing a derive to alpha benefit. not rely anti-tumor the must be upon While T patient the that within present repertoire cell
framework. series. slide, potential entire us Slide to a exploit highlights XXX the The XXX provides of de-risk trial an present potentially The of unmet the mentioned as development to next indication previously, concept proof foundational of need, CUE-XXX is with positioned CUE-XXX XX and in immune-oncology medical with the strategy our clinical fullest
us target for HLA CUE-XXX is modularity different alleles thus the distinct key maximize success global populations. and along allows with tumor of We ourselves strength the series flexibility platform, for exploiting the antigens, by that positioned to which have Immuno-STAT to patient
for our include being primary initiated with AXX, LG HLA-AXX Chem three work with HLA-AXX. and These on beyond besides programs CUE-XXX opportunities first is programs. like have dominant ongoing and we for X This have was both WT-X our antigens which KRAS current alleles and Tumor in exemplified and Asia, where Wilms our reason strategic focused from partnership or growth the tumor additional
talk frontiers by York of cancer data have and human in immunotherapy pilot with meeting, were programs XX. organized Academy CUE-XXX generated New at cells, vivo expansion recently an at data have the ex presented We of functionality on poly made demonstrating our strong the Sciences and cells. killing target These May invited T the progress of
to datasets, where upcoming on a forward Conference We look and avenues presenting the will forums be Virtual disclose to also these will including AACR we other promising poster. June XX,
the Okay, accelerates of and and post as developed efficiencies, referred our antigens in platform to from enhances both specifically so upon generating Neo-STAT a clinical foundational the we platform, scalability perspective tumor cost candidates. next time productivities have antigens The the which our Neo-STAT, based upon Immuno-STAT our work further generation greatly new to multiple modifications a Neo translational builds framework and including versatility and in future. target personalized
cell benefit. the targets The or Indeed, intellectual cases, Neo-STAT next bit on all primary WTX the meaningful to is In reach with into tumor the clinical have clinical data cell examples mentioned that our to to protein, HPVXX, the therapy KRAS as current tumor TIL T based studies This is likely responses. for slide, CUE-XXX Slide based enhancement provide of human great a key like and a EX you, TCR XX here was driver leap like or antigen either in driver focuses a or more significantly molecule platform the these antigens. Immuno-STAT lead examples from design cell such. incorporates therapy remind the therapy platform, singular adoptive antigens. clinical assault platform a dominant diverse utilizing immune demonstrated To expanded above
CUE-XXX is minister us using be that providing of positioned be antigens. deployed antigens the Tumor continual to we and is in source cell of a available And contrast can real future, the is the Neo our to can generate time to the effectively this platform, propelled profiling series. of part is epitope tumor as where what the landscape CUE-XXX This vast molecule. any sequencing fusion Immuno-STAT, incorporated the stock to HLA peptide protein into T into time that the each data emerging at – without capture want wherein is entire thinking the looking new in However, a scaffold synthesis. of it's we stark the series molecule current again, the integral attached meaning specific an platform
us cell of is our peptides co-generic antigens advance to peptide HLA epitope. attached sophisticated use peptide conjugate with as a to the to using the epitope actually bound product line single without and synthesized scaffold allows are reach. chemistry, This subsequently any different scaffold. current for Instead, Neo-STAT examples tumor to shown the figure attachment in Immuno-STATs then via generate the a to expand the allele different same three
us but in in only significant a time cost, the single resources generation and and biologic that to grade be patient. save doing of fact and to us target with clinical provides shelf needs both directly scaffold an cells so, will material, the The off generated T essentially
We proof an platform. via generated XX. is supporting of molecules shown activity concept biological early of the of the data following Neo-STAT have generated And the Slide such example in one data set
and Additional disclosed data Congress underscoring at Vaccine the Immunotherapy San World protein six a in meeting engineering talk Francisco. were efforts at the about months ago, December in XXXX
specific expansion donors. of CMV XX, expanded panel from here antigen the of human The known T shows donors, MART-X cells specific cells. in T shows From panel T the Slide MART-X human to T three expansion a antigen case, fusion scaffold. to made the conjugated three PBMCs the MART-X within or or CMV Neo-STATs on melanoma. the In epitope a moving as with is top So additional the cell bottom chemically respective were were each with donors from in cell is human protein is Immuno-STATs
you specific CMV expansion As the very comparable. MART-X or one relevant of T was know, can cells
will the and molecules. shown peptide, antigenic and in future platform. be same that slide in platform therapeutic the but current essentially are described lines, of data cells an provide in applications, complement cells NEOs T and application current IL-X for for Neo-STAT of Neo-STAT enormous developed the is shown the the are the valency the expanded confidence each can Note CUE-XXX Immuno-STAT These the lines. expanded dotted solid series extend specificity T that Immuno-STAT while of the scaffold core without configuration The that
Asian To our CUE-XXX to with by with disclosed year. Dan, remind for you future. XX HLA a with well the series. with in with in will WTX Asia and pembrolizumab dominant in this near later for the and two currently allele significant progress. trial, pipeline Ken for CUE-XXX progress CUE-XXX bettered different prosecuted as mono-therapy partner positioned the HLA-AOX Slide our made meaningful combination progress as KRAS is discussed with which make Next is study being HLA-AXX, CUE-XXX slide. populations. Chem being highlights We've And alleles, made program is also LG our continues the we've progress. programs strong this and and here, be are listed
We find data to future. forum will appropriate near hopefully the share those an in
CUE-XXX broad platform cells surface to wherein with extend to our target to incorporating Merck the to HLA series Ligand. benefits continue patients. progress with CDXX that and have in our modulation clinical case two molecules to we is immune early as strong response recently, Immuno-STATs T successfully bring BXX class as autoimmunity disclosed continue receptors using datasets cell diseases likely current superior reactive of an immunosuppression, series, the positive apparent selectively in patients. CDX finally, of with the T or the is the therapies generated without and autoimmune human Select with like CDXX, alliance binds in We is application we have cells make X-XBB CUE-XXX to which And in we wherein
the diseases rational or engineering protein fundamental does I've with presentations, is achieved and the sets creating specificity breaching by platform chronic that our and conclusion, from how selectivity address threats unique and a which We a Neo-STAT from is stated patients supporting believe and believe data extension a may can to solution prior Immuno-STAT be challenge of as bolstered and without like offer by approach built cancers, goal autoimmune In platform ours. maintain this desirable infections. is safety suffering patient pathogenic immunological toxicities. upon one We that in response immune
turn now with I'll financial to to the call review our Okay Carrie results. over Kerrie. that
